A transition metal complex (Venus flytrap cluster) for radioimmunodetection and radioimmunotherapy ( 
The use of monoclonal and engineered antibodies for the selective delivery of diagnostic and therapeutic radiometals to tumors requires suitable bifunctional reagents that efficiently form covalent bonds with antibody and stable radionuclide chelate complexes. With few exceptions, monoclonal antibody (mAb)-chelator conjugates have been prepared with bifunctional reagents that are members of the aminocarboxylate chelator family, with derivatives of diethylenetriaminepentaacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA) being most popular (1) (2) (3) (4) (5) . These conjugates form stable radiopharmaceuticals with 1"'In that have been used for radioimmunodiagnosis of human tumors (6) (7) (8) , although there is some concern about their uptake by normal tissues and possible metal release in vivo. Conjugates of this type, however, form less stable radiopharmaceuticals with 90Y and 67Cu (9, 10) , which can be used for radioimmunotherapy. There is therefore considerable interest in the development of new bifunctional reagents that will form more stable chelate complexes with these and other clinically relevant radionuclides.
Radionuclides such as 67Cu, 991Tc, 105Rh, and '86Re are transition metals. Thus, very efficient ir-bonding ligands would be expected to form complexes of great stability with these radionuclides. Hawthorne and coworkers (11, 12) first described commo-bisdicarbollide transition metal complexes in which the metal ion is held between two ir-bonding
[C2B9H11]2-dicarbollide ligands. With d6 metal ions these complexes conform to both the 18-electron and cluster electron-counting rules and display extraordinary stability due to the cluster bonding of the transition metal with ligand orbitals of appropriate symmetry. Metal ions having other than six d electrons, such as d3Cr3+ and d8Cu3+, also form stable bis-dicarbollide clusters, although in the case of electron-rich (d7, d8, etc.) species, the dicarbollide ligands undergo a "slip" distortion (12) . The ability to produce these complexes in high yield in aqueous media, their expected stability to physiological conditions, and their expected resistance to enzyme degradation systems suggested their use in bifunctional reagents for transition metals. We have designed, synthesized, and characterized a prototype bridged commobisdicarbollide bifunctional reagent appropriate for mAb conjugates (13) . This metal-containing reagent has been designated Venus flytrap cluster (VFC). The present report describes the preparation of a radiolabeled mAb using VFC and its initial in vivo evaluation.
MATERIALS AND METHODS
Antibody and Tumor Cell Line. Anti-carcinoembryonic antigen (CEA) mAb T84.66 (14, 15) was used for radiolabeling. T84.66 is a murine IgG1, is specific for CEA, does not crossreact with granulocytes or other normal tissues, and has an affinity constant for CEA of >2 x 1010 M-1. DTPAconjugated T84.66 was prepared as described (16) Immunoreactivity. Microtiter plates coated with CEA (10 ,ug/ml) were incubated with serial dilutions of T84.66 and 57Co-VFC-T84.66. A double sandwich enzyme immunoassay was then performed, and the resulting binding curves were compared. Anti-CEA mAb was quantified as described (18) . SDS/Polyacrylamide Gel Electrophoresis (SDS/PAGE). T84.66 and 57Co-VFC-T84.66 were electrophoresed in 10%o (wt/vol) polyacrylamide gels by the method of Laemmli (19) .
Samples were heated at 100°C in 62.5 mM Tris, pH 7.5/20%o (vol/vol) glycerol/2% (wt/vol) SDS with 5% (vol/vol) 2-mercaptoethanol (reducing conditions) or without 2-mercaptoethanol (nonreducing conditions) prior to electrophoresis. Gels were stained with Coomassie blue R-250 or exposed to X-Omat film (Kodak) for autoradiography.
RESULTS
The synthesis of the VFC ligand and the preparation and characterization of Co-VFC have been described (13) . The structure ofCo-VFC as determined by x-ray diffraction is shown in Fig. 1 . The preparation of 57Co-VFC followed a similar scheme, but on a much smaller scale. Briefly, 57CoC12 was incubated with a large excess of the VFC ligand in 2 M NaOH. The basic conditions removed B-H-B bridge hydrogen atoms present on each [7,9- (Fig. 2, lanes 1 and 2) and nonreducing (lanes 4 and 5) conditions. The molecular weight of >200,000 for this antibody under nonreducing conditions (lanes 4 SDS/PAGE of 57Co-VFC-T84.66 under reducing conditions (Fig. 2, lane 3) showed only a trace of radioactivity at the electrophoretic front (ca. 22 kDa). This demonstrated that 57Co-VFC-T84.66 was stable to the sample preparation procedure-i.e., 5 min at 100°C in 2% SDS/5% 2-mercaptoethanol-and confirmed the robust nature of the transition metal complex. These conditions completely dissociate "'1In from DTPA-conjugated antibodies (data not shown). Enzyme immunoassay of 57Co-VFC-T84.66 and unconjugated T84.66 on CEA-coated microtiter plates showed equivalent reactivities, demonstrating retention of immunoreactivity for the radiolabeled mAb.
Tumor localization with 57Co-VFC-T84.66 was demonstrated in nude mice bearing single xenografts of LS174T human colon cancer cells. A dose of 10 ,ug of 57Co-VFC-T84.66 resulted in 12.74 ± 0.31 %ID/g in tumor, 7.59 ± 0.53 %ID/g in liver, and <4 %ID/g in the other normal tissues (Fig. 3 to tumor-bearing mice resulted in tumor uptakes of 11.96 ± 1.06 %ID/g and 12.51 ± 0.59 %ID/g for 10-,ug and 100-,ug doses, respectively (Fig. 3 Lower) . These values were comparable to those seen with 57Co-VFC-T84.66. However, the uptake of radiolabel in liver (22.74 ± 0.69 %ID/g) and spleen (12.88 ± 1.20 %ID/g) for the 10-I&g dose of "tIn-DTPA-T84.66 was significantly higher than for either dose of 57Co-VFC-T84.66 (P < 0.0002). Increasing the dose of "1'In-DTPA-T84.66 to 100 ,ug reduced the amount of radiolabel in the liver (7.42 ± 0.82 %ID/g) and spleen (4.45 ± 0.31 %ID/g) to values similar to those seen for the VFC conjugate. Animals with similar tumor masses were used in these comparisons to minimize the effects of tumor size on the biodistribution (20) .
Comparison of the biodistributions of the 57Co-VFC and 111In-DTPA conjugates (Fig. 3) indicated that with the exception of blood, there was an overall lower retention of radiolabel by normal tissue in the mice injected with 57Co-VFC-T84.66. This difference was most marked at the 10-pg dose.
Tumor/liver (T/L) and tumor/blood (T/B) ratios were used as a quantitative measure of the effectiveness of antibody localization (Table 1) . At the 10-,ug antibody dose, the T/B ratio was higher with '11In-DTPA-T84.66 (5.99 ± 0.53) than with 57Co-VFC-T84.66 (3.57 ± 0.41), but at the high antibody doses, the T/B ratios for the two conjugates were decreased to comparable values. The decrease in the T/B ratios at the higher doses reflects an increased amount of antibody in the blood, because tumor levels remained nearly the same. The T/L ratio at the 10-,ug dose for 57Co-VFC-T84.66 was almost 3 times higher than for 111In-DTPA-T84.66. At the high antibody doses, the T/L ratio for 57Co-VFC-T84.66 was unchanged, whereas the T/L ratio for 111In-DTPA-T84.66 increased from 0.58 ± 0.06 to 1.75 ± 0.17. The 57Co-VFC-T84.66 conjugate gave T/L ratios that were significantly higher at both the low dose (P < 0.05) and the high dose (P < 0.002) of antibody relative to comparable doses of "11In-DTPA-T84.66. Overall, the 10-,ug dose of 57Co-VFC-T84.66 gave the most favorable combination of T/L and T/B ratios.
Tumor localization was also demonstrated by immunoscintigraphy of a single animal at four time points after injection of the 130-,ug dose of 57Co-VFC-T84.66. As shown in Fig. 4 , tumor uptake increased relative to that of normal tissue over the period from 24 hr to 96 hr. Biodistribution data at 168 hr of mice injected with the same dose also reflected this observation, giving T/L and T/B ratios of 3.48 ± 0.32 and 1.40 + 0.12, respectively, which were slightly higher than those observed at 48 hr (Table 1) . Biodistribution results with 57Co-VFC-T84.66 showed excellent tumor uptake, whereas radionuclide accumulation in normal tissues, especially liver, was low. This is in contrast to 1"'In-labeled mAbs, which often show high levels of radionuclide in liver. The mechanisms of radionuclide accumulation in liver and other normal tissues are not fully understood, although they are thought to be dependent on both the uptake of radiolabeled mAb by normal tissues and its subsequent processing (30) . We have previously shown that the high uptake of '11In-DTPA-T84.66 in the liver is in part related to the formation of antigen-antibody complexes (23) (24) (25) . The decrease in liver uptake of "tIn-DTPA-T84.66 shown here at the higher antibody dose was in agreement with our earlier studies in which liver uptake was strongly dependent on antibody dose (23) . The low liver uptake and independence of antibody dose demonstrated by 57Co-VFC-T84.66 could therefore be due to a decrease in the formation of these complexes; however, the retention of full immunoreactivity for 57Co-VFC-T84.66 and its targeting to tumor suggest that the mAb was fully capable of forming antigenantibody complexes. A more probable explanation for the low liver accumulation of 57Co-VFC-T84.66 is that the processing of the conjugate and the subsequent excretion of 57Co-VFC from the liver are accelerated relative to the 11In-DTPA conjugate.
In previous studies, we have shown in animals injected with 111In-DTPA-T84.66 that the radionuclide is retained in the liver in the form of low molecular weight components likely to be catabolites of the radiolabeled mAb (24, 25) . Using the same methods, we have not detected 57Co-labeled low molecular weight components in animals receiving 57Co-VFC-T84.66 (31) . Further, the amount of radioactivity in feces is greater for the 57Co-VFC conjugate than for the 111In-DTPA conjugate (unpublished data). The chemical stability of 57Co-VFC, its unique structure and chemical properties compared with "1In-DTPA, and its expected resistance to biological degradation may be important factors in this apparently accelerated excretion mechanism.
Several clinically useful transition metal radionuclides can potentially be accommodated by the VFC architecture. 67Cu is very promising for radioimmunotherapy because of its half-life of 61.5 hr, abundant 3 particles, and y emissions suitable for imaging. DTPA-and EDTA-conjugated mAbs form unstable complexes with 67Cu (10), although stable complexes have been obtained using 6-p-bromoacetamidobenzyl-1 ,4,8,11-tetraazacyclotetradecane-N,N' ,N" ,N "-tetraacetate, a macrocyclic aminocarboxylate bifunctional reagent (10, 32, 33) . The rigidity of the bifunctional VFC ligand described here prevents the formation of the "slipped" structure characteristic of Cu3+ bisdicarbollide clusters (12); however, this structure can most likely be achieved by introducing greater flexibility into the VFC ligand through the use of 3-or 4-atom bridges, rather than the 2-atom bridge provided by pyrazole. Based on our results with 57Co-VFC-T84.66, we anticipate that mAb conjugates prepared with a VFC ligand suitable for 67Cu would be extremely stable and would provide excellent tumor/normal tissue ratios.
